Aspirin and heparin in pregnancy

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 12, 2015, Pages 1793-1803

  Grandone, Elvira ^a   Villani, Michela ^a   Tiscia, Giovanni L ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

aspirin; gestational vascular complications; heparin; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; FIBRINOLYTIC AGENT;

ANTIPHOSPHOLIPID SYNDROME; DRUG EFFICACY; GESTATIONAL VASCULAR COMPLICATION; HIGH RISK PATIENT; HUMAN; INFERTILITY THERAPY; LIVE BIRTH; NONHUMAN; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; THROMBOPHILIA; TREATMENT OUTCOME; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; FEMALE; PREGNANCY COMPLICATIONS; RISK; VASCULAR DISEASES;

ANTICOAGULANTS; ASPIRIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; REPRODUCTIVE TECHNIQUES, ASSISTED; RISK; THROMBOPHILIA; VASCULAR DISEASES; VENOUS THROMBOEMBOLISM;

EID: 84937688005     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1066335     Document Type: Review

References (102)

1. McLean KC, Bernstein IM, Brummel-Ziedins KE. Tissue factordependent thrombin generation across pregnancy. Am J Obstet Gynecol 2012; 207: 135e1-6
2. Aharon A, Brenner B, Katz T, et al. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. Thromb Haemost 2004; 92: 776-86
3. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 153-68
4. Lussana F, Coppens M, Cattaneo M, Middeldorp S. Pregnancy-related venous thromboembolism: risk and the effect of thromboprophylaxis. Thromb Res 2012; 129: 673-80
5. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194: 1311-15
6. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632-7
7. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study. Ann Intern Med 2005; 10: 697-706
8. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-19
9. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13
10. Middeldorp S. Pregnancy failure and heritable thrombophilia. Semin Hematol 2007; 44: 93-7
11. Rai R, Regan L. Recurrent miscarriage. Lancet 2006; 368: 601-11
12. Greer IA, Brenner B, Gris JC. Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine? Br J Haematol 2014; 165: 585-9
13. de Jong PG, Kaandorp S, Di Nisio M, et al. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev 2014
14. Duffett L, Rodger M. LMWH to prevent placenta-mediated pregnancy complications: an update. Br J Haematol 2015; 168: 619-38
15. Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2013; 7: CD006780
16. Chinni E, Colaizzo D, Tiscia GL, et al. Markers of haemostasis and angiogenesis in placentae from gestational vascular complications: impairment of mechanisms involved in maintaining intervillous blood flow. Thromb Res 2010; 125: 267-71
17. Bogdanova N, Horst J, Chlystun M, et al A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy loss. Hum Mol Genet 2007; 16: 573-8
18. Grandone E, Tiscia G, Colaizzo D, et al. Role of the M2 haplotype within the annexin A5 gene in the occurrence of pregnancy-related venous thromboembolism. Am J Obstet Gynecol 2010; 203: 461.e1-5
19. Tiscia G, Colaizzo D, Chinni E, et al. Haplotype M2 in the annexin A5 (ANXA5) gene and the occurrence of obstetric complications. Thromb Haemost 2009; 102: 309-13
20. Bain E, Wilson A, Tooher R, et al. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2014; 2: CD001689
21. Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol 1997; 11: 489-509
22. Greer IA, Brenner B, Gris JC. Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine? Br J Haematol 2014; 165: 585-99
23. Greer IA. Antithrombotic therapy for pregnancy complications: let's not throw the baby out with the bath water. Evid Based Med 2015; 20: 10
24. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 2: 295-306
25. Meroni PL, Tedesco F, Locati M, et al. Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. Lupus 2010; 19: 453-6
26. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330-9
27. Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 2010; 19: 460-9
28. Robbins DL, Leung S, Miller-Blair DJ, Ziboh V. Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 1998; 25: 51-6
29. Grandone E, Tomaiuolo M, Colaizzo D, et al. Role of thrombophilia in adverse obstetric outcomes and their prevention using antithrombotic therapy. Semin Thromb Hemost 2009; 35: 630-43
30. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-18
31. Smyth EM, Grosser T, Wang M, et al. Prostanoids in health and disease. J Lipid Res 2009; 50(Suppl): S423-8
32. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68: 11B-5B
33. Kliman HJ. Uteroplacental blood flow. The story of decidualization, menstruation, and trophoblast invasion. Am J Pathol 2000; 157: 1759-68
34. Bussolino F, Benedetto C, Massobrio M, Camussi G. Maternal vascular prostacyclin activity in pre-eclampsia. Lancet 1980; 2: 702
35. Patrono C, Garciá Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83
36. American College of Obstetricians ad Gynecologists Committee on Obstetric Practice. ACOG practice bulletin, number 33, January 2002. Diagnosis and management of preeclampsia and eclampsia. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 77: 67-75
37. Fitzgerald DJ, Rocki W, Murray R, et al. Thromboxane A2 synthesis in pregnancyinduced hypertension. Lancet 1990; 335: 751-4
38. Woods LL. Importance of prostaglandins in hypertension during reduced uteroplacental perfusion pressure. Am J Physiol 1989; 257: R1558-61
39. Schisterman EF, Silver RM, Lesher LL, et al. Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet 2014; 384: 29-36
40. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 2000; 31: 1779-84
41. Baron JA, Senn S, Voelker M, et al. Gastrointestinal adverse effects of shortterm aspirin use: a meta-Analysis of published randomized controlled trials. Drugs R D 2013; 13: 9-16
42. James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. Obstet Gynecol Surv 2008; 63: 49-57
43. Ghidini A. Overview of low molecular weight heparin for preventative treatment of adverse obstetric outcomes related to abnormal placentation. Prenat Diagn 2014; 34: 649-54
44. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-18
45. Abildgaard U. Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 1968; 21: 89-91
46. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975; 292: 146-51
47. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S
48. Sobel M, Fish WR, Toma N, et al. Heparin modulates integrin function in human platelets. J Vasc Surg 2001; 33: 587-94
49. Cella G, Scattolo N, Luzzatto G, Girolami A. Effects of low-molecular-weight heparin on platelets as compared with commercial heparin. Res Exp Med (Berl) 1984; 184: 227-9
50. Cella G, Girolami A, Sasahara AA. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1999; 99: 3323
51. Xiao Z, Th-eroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-6
52. Salzman EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
53. Brace LD, Fareed J. Heparin-induced platelet aggregation: dose/response relationships for a low molecular weight heparin derivative (PK 10169) and its subfractions. Thromb Res 1986; 42: 769-82
54. Oberkersch R, Attorresi AI, Calabrese GC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res 2010; 125: e240-5
55. Quenby S, Mountfield S, Cartwright JE, et al. Effects of low-molecular-weight and unfractionated heparin on trophoblast function. Obstet Gynecol 2004; 104: 354-61
56. Ganapathy R, Whitley GS, Cartwright JE, et al. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod 2007; 22: 2523-7
57. Reantragoon S, Arrigo LM, Seoud MM, et al. Specific heparin fractions suppress endothelin-1 production in cultured human umbilical vein endothelial cells. Arch Biochem Biophys 1994; 314: 315-22
58. Torricelli M, Reis FM, Florio P, et al. Low-molecular-weight heparin improves the performance of uterine artery Doppler velocimetry to predict preeclampsia and small-for-gestational age infant in women with gestational hypertension. Ultrasound Med Biol 2006; 32: 1431-5
59. Walker ID, Kujovich JL, Greer IA, et al. The use of LMWH in pregnancies at risk: new evidence or perception? J Thromb Haemost 2005; 3: 778-93
60. Shapiro NL, Kominiarek MA, Nutescu EA, et al. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: singlecenter experience. Pharmacotherapy 2011; 31: 678-85
61. Chowdary P, Adamidou D, Riddell A, et al. Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy: implications for anticoagulant monitoring. Br J Haematol 2015; 168: 719-27
62. Guimicheva B, Czuprynska J, Arya R. The prevention of pregnancy-related venous thromboembolism. Br J Haematol 2015; 168: 163-74
63. Jilma B, Kamath S, Lip GY. ABC of antithrombotic therapy: Antithrombotic therapy in special circumstances. II-In children, thrombophilia, and miscellaneous conditions. BMJ 2003; 326: 93-6
64. Hillis CM, Crowther MA. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2015; 113: 1193-202
65. Galambosi PJ, Kaaja RJ, Stefanovic V, Ulander VM. Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study. Eur J Obstet Gynecol Reprod Biol 2012; 163(2): 154-9
66. Vanassche T, Vandenbriele C, Peerlinck K, Verhamme P. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. Expert Opin Pharmacother 2015; 16: 645-58
67. Cutts BA, Dasgupta D, Hunt BJ. New directions in the diagnosis and treatment of pulmonary embolism during pregnancy. Am J Obstet Gynaecol 2013; 208: 102-8
68. Turpie AGG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban-An oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108: 876-86
69. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362: 1586-96
70. Clark P, Walker ID, Langhorne P, et al. Scottish Pregnancy Intervention Study (SPIN) collaborators. Blood 2010; 115: 4162-7
71. Pasquier E, de Saint Martin L, Bohec C, et al. Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. Blood 2015; 125(14): 2200-5
72. Schleussner E, Kamin G, Seliger G, et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Ann Intern Med 2015; 162: 601-9
73. Henderson JT, Whitlock EP, O'Connor E, et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the us Preventive Services Task Force. Ann Intern Med 2014; 160: 695-703
74. Villa PM, Kajantie E, Räikkonen K, et al. Aspirin in the prevention of preeclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-Analysis of randomised trials. BJOG 2013; 120: 64-74
75. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-Analysis. Obstet Gynecol 2010; 116: 402-14
76. Kwak-Kim J, Agcaoili MS, Aleta L, et al. Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome. Am J Reprod Immunol 2013; 69: 596-607
77. Di Prima FA, Valenti O, Hyseni E, et al. Antiphospholipid Syndrome during pregnancy: the state of the art. J Prenat Med 2011; 5: 41-53
78. Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al.comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 2014; 123: 404-13
79. Grandone E, Brancaccio V, Colaizzo D, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002; 78: 371-5
80. Tormene D, Grandone E, De Stefano V, et al. Obstetric complications and pregnancy-related-venous thromboembolism: the effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. Thromb Haemost 2012; 107: 477-84
81. Grandone E, De Stefano V, Rossi E, et al. Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants. Blood Coagul Fibrinolysis 2008; 19: 226-30
82. Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 2014; 384: 1673-83
83. Martinelli I, Ruggenenti P, Cetin I, et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012; 119: 3269-75
84. Rodger MA, Carrier M, Le Gal G, et al. Meta-Analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 2014; 123: 822-8
85. Gris JC. Thrombophilia and pregnancy loss: cause or association. Thromb Res 2009; 123(Suppl 2): S105-10
86. Grandone E, Colaizzo D, Tiscia G, Margaglione M. More on: factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first-intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost 2006; 4: 709-10
87. Akhtar MA, Sur S, Raine-Fenning N, et al. Heparin for assisted reproduction. Cochrane Database Syst Rev 2013; 8: CD009452
88. Luley L, Schumacher A, Mulla MJ, et al. Low molecular weight heparin modulates maternal immune response in pregnant women and mice with thrombophilia. Am J Reprod Immunol 2015; 73(5): 417-27
89. Dentali F, Grandone E, Rezoagli E, Ageno W. Efficacy of low molecular weight heparin in patients undergoing in vitro fertilization or intracytoplasmic sperm injection. J Thromb Haemost 2011; 9: 2503-6
90. Grandone E, Villani M, Tiscia GL, et al. Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience. PLoS ONE 2014; 9: e97604
91. Grandone E, Villani M, Tiscia GL, et al. Clinical Pregnancies and Live Births in women approaching ART: a follow-up analysis of 157 women after thrombophilia screening. Thromb Res 2014; 133: 168-72
92. Grandone E, Villani M, Dentali F, et al. Low-molecular-weight heparin in pregnancies after ART-A retrospective study. Thromb Res 2014; 134: 336-9
93. Dentali F, Ageno W, Rezoagli E, et al. Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-Analysis of the literature. J Thromb Haemost 2012; 10: 2075-85
94. Siristatidis CS, Dodd SR, Drakeley AJ. Aspirin for in vitro fertilisation. Cochrane Database Syst Rev 2011(8): CD004832
95. Confidential enquiries into maternal and Child Health. Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer, 2006-08. The eighth report of the confidential enquires into maternal deaths in the United Kingdom. CEMACH; London: 2011
96. Donati S, Senatore S, Ronconi A; Regional maternal mortality working group. Maternal mortality in Italy: a record-linkage study. BJOG 2011; 118: 872-9
97. Romualdi E, Dentali F, Rancan E, et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-Analysis of the literature. J Thromb Haemost 2013; 11: 270-81
98. Andersen AS, Berthelsen JG, Bergholt T. Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin. Acta Obstet Gynecol Scand 2010; 89: 15-21
99. Hansen AT, Kesmodel US, Juul S, Hvas AM. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod 2014; 29: 611-17
100. Henriksson P, Westerlund E, Wall-en H, et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ 2013; 346: e8632
101. Grandone E, Villani M. Assisted reproductive technologies and thrombosis. Thromb Res 2015; 135(Suppl 1): S44-5
102. Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril 2012; 97: 95-100